European Journal of Cancer
Volume 39, Issue 13 , Pages 1899-1903 , September 2003

Tumour markers are poor predictors for relapse or progression in neuroblastoma

  • T. Simon

      Affiliations

    • Children's Hospital, Department of Pediatric Haematology and Oncology, University of Cologne, Joseph-Stelzmann-Straße 9, 50924 Cologne, Germany
    • Corresponding Author InformationCorresponding author. Tel.: +49-221-478-4380; fax: +49-221-478-6801
    • ,
  • B. Hero

      Affiliations

    • Children's Hospital, Department of Pediatric Haematology and Oncology, University of Cologne, Joseph-Stelzmann-Straße 9, 50924 Cologne, Germany
    • ,
  • D.H. Hunneman

      Affiliations

    • Children's Hospital, University of Göttingen, Germany
    • ,
  • F. Berthold

      Affiliations

    • Children's Hospital, Department of Pediatric Haematology and Oncology, University of Cologne, Joseph-Stelzmann-Straße 9, 50924 Cologne, Germany

Received 14 January 2003 ,Revised 10 March 2003 ,Accepted 17 April 2003.

References 

  1. Bond JV. Clinical significance of catecholamine excretion levels in diagnosis and treatment of neuroblastoma. Arch. Dis. Child. 1975;50:691–695
  2. Berthold F, Hunneman DH, Harms D, et al.  Serum vanillylmandelic acid/homovanillic acid contributes to prognosis estimation in patients with localised but not with metastatic neuroblastoma. Eur. J. Cancer. 1992;28A:1950–1954
  3. Brodeur GM, Pritchard J, Berthold F, et al.  Revisions of the international criteria for neuroblastoma diagnosis, staging, and response to treatment. J. Clin. Oncol. 1993;11:1466–1477
  4. Hero B, Hunneman DH, Gahr M, et al.  Evaluation of catecholamine metabolites, mIBG scan, and bone marrow cytology as response markers in stage 4 neuroblastoma. Med. Ped. Oncol. 2001;36:220–223
  5. Massaron S, Seregni E, Luksch R, et al.  Neuron-specific enolase evaluation in patients with neuroblastoma. Tumour Biol. 1998;19:261–268
  6. Brodeur GM, Seeger RC, Berrett A, et al.  International criteria for diagnosis, staging, and response to treatment in patients with neuroblastoma. J. Clin. Oncol. 1988;6:1874–1881
  7. Berthold F. Neuroblastom. In:  Schmoll H-J,  Höffgen K,  Possinger K editor. Kompendium Internistische Onkologie. Springer: Berlin; 1997;p. 1805–1819
  8. Berthold F, Hero B. Neuroblastoma (current drug therapy recommendations as part of the total treatment approach). Drugs. 2000;59:1261–1277
  9. Hunneman DH. Mass fragmentographic determination of homovanillic and 4-hydroxy-3-methoxy mandelic acids in 50 μl plasma. Clin. Chim. Acta. 1983;135:169–174
  10. Hunneman DH, Jonas W, Gabriel M, et al.  Effect of age on homovanillic and 4-hydroxy-3-methoxymandelic acid levels in plasma. Eur. J. Pediatr. 1986;145:555–557
  11. Berthold F, Engelhardt-Fahrner U, Schneider A, et al.  Age dependence and prognostic impact of neuron specific enolase (NSE) in children with neuroblastoma. In Vivo. 1991;5:245–248
  12. Reuland P, Geiger L, Thelen MH, et al.  Follow-up in neuroblastoma (comparison of metaiodobenzylguanidine and chimeric anti-GD2 antibody for detection of tumour relapse and therapy response). J. Pediatr. Hematol. Oncol. 2001;23:437–442
  13. Okuyama C, Ushijima Y, Kubota T, et al.  Utility of follow-up studies using meta-(123I)iodobenzylguanidine scintigraphy for detecting recurrent neuroblastoma. Nucl. Med. Commun. 2002;23:663–672

PII: S0959-8049(03)00376-9

doi: 10.1016/S0959-8049(03)00376-9

European Journal of Cancer
Volume 39, Issue 13 , Pages 1899-1903 , September 2003

Article Tools

* Image Usage & Resolution